Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2015, Article ID 351601, 7 pages
http://dx.doi.org/10.1155/2015/351601
Research Article

A Cross-Sectional Study Demonstrating Increased Serum Amyloid A Related Inflammation in High-Density Lipoproteins from Subjects with Type 1 Diabetes Mellitus and How This Association Was Augmented by Poor Glycaemic Control

1Centre for Public Health, Queen’s University Belfast, Institute of Pathology, Grosvenor Road, Belfast BT12 6BJ, UK
2Department of Endocrinology, Tallaght Hospital, Dublin 24, Ireland

Received 27 August 2014; Accepted 8 October 2014

Academic Editor: Gareth McKay

Copyright © 2015 Jane McEneny et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. D. de Ferranti, I. H. de Boer, and V. Fonseca, “Type 1 diabetes mellitus and cardiovascular disease. A scientific statement from the American Heart Association and American Diabetes Association,” Circulation, vol. 130, pp. 1110–1130, 2014. View at Google Scholar
  2. J. Guy, L. Ogden, R. P. Wadwa et al., “Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for diabetes in youth case-control study,” Diabetes Care, vol. 32, no. 3, pp. 416–420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. L. Meek, S. Urieli-Shoval, and E. P. Benditt, “Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 8, pp. 3186–3190, 1994. View at Publisher · View at Google Scholar · View at Scopus
  4. J.-L. Du, J.-F. Liu, L.-L. Men et al., “Effects of five-year intensive multifactorial intervention on the serum amyloid A and macroangiopathy in patients with short-duration type 2 diabetes mellitus,” Chinese Medical Journal, vol. 122, no. 21, pp. 2560–2566, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Zhi, A. Sharma, S. Purohit et al., “Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays,” Molecular & Cellular Proteomics, vol. 10, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. K. Heliövaara, A.-M. Teppo, S.-L. Karonen, J. A. Tuominen, and P. Ebeling, “Improved glycaemia in type 1 diabetes results in decreased levels of soluble adhesion molecules with no change in serum adiponectin or most acute phase proteins,” Experimental and Clinical Endocrinology and Diabetes, vol. 114, no. 6, pp. 295–300, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Chiba, C. Y. Han, T. Valsar et al., “Serum amyloid A3 does not contribute to circulating SAA levels,” Journal of Lipid Research, vol. 50, no. 7, pp. 1353–1362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. L. L. Bausserman and P. N. Herbert, “Degradation of serum amyloid A and apolipoproteins by serum proteases,” Biochemistry, vol. 23, no. 10, pp. 2241–2245, 1984. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Scanu and W. L. Hughes, “Further characterization of the human serum D 1.063-1.21, α1-lipoprotein,” The Journal of Clinical Investigation, vol. 41, no. 8, pp. 1681–1689, 1962. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Artl, G. Marsche, S. Lestavel, W. Sattler, and E. Malle, “Role of serum amyloid A during metabolism of acute-phase HDL by macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 3, pp. 763–772, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. J. B. Ancsin and R. Kisilevsky, “Serum amyloid A peptide interactions with glycosaminoglycans. Evaluation by affinity chromatography,” Methods in Molecular Biology, vol. 171, pp. 449–456, 2001. View at Google Scholar · View at Scopus
  12. V. L. King, J. Thompson, and L. R. Tannock, “Serum amyloid A in atherosclerosis,” Current Opinion in Lipidology, vol. 22, no. 4, pp. 302–307, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. McPherson, I. S. Young, B. McKibben, and J. McEneny, “High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation,” The Journal of Lipid Research, vol. 48, no. 1, pp. 86–95, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. T. A. Pearson, G. A. Mensah, R. W. Alexander et al., “Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association,” Circulation, vol. 107, no. 3, pp. 499–511, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Farmer and J. Liao, “Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis,” Current Atherosclerosis Reports, vol. 13, no. 2, pp. 107–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Hine, B. MacKness, and M. MacKness, “Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation,” IUBMB Life, vol. 64, no. 2, pp. 157–161, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Loued, M. Isabelle, H. Berrougui, and A. Khalil, “The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins,” Life Sciences, vol. 90, no. 1-2, pp. 82–88, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Mackness, P. N. Durrington, and M. I. Mackness, “Human serum paraoxonase,” General Pharmacology, vol. 31, no. 3, pp. 329–336, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. P. M. M. Weers, A. B. Patel, L. C.-P. Wan et al., “Novel N-terminal mutation of human apolipoprotein A-I reduces self-association and impairs LCAT activation,” Journal of Lipid Research, vol. 52, no. 1, pp. 35–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Qiu, A. Mistry, M. J. Ammirati et al., “Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules,” Nature Structural and Molecular Biology, vol. 14, no. 2, pp. 106–113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Eriksen and E. P. Benditt, “Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 11 I, pp. 6860–6864, 1980. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Chiba, M. Y. Chang, S. Wang et al., “Serum amyloid a facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 6, pp. 1326–1332, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Kontush and M. J. Chapman, “Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis,” Pharmacological Reviews, vol. 58, no. 3, pp. 342–374, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Festa, R. D'Agostino Jr., G. Howard, L. Mykkänen, R. P. Tracy, and S. M. Haffner, “Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS),” Circulation, vol. 102, no. 1, pp. 42–47, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. F. B. Filippin-Monteiro, E. M. de Oliveira, S. Sandri, F. H. Knebel, R. C. Albuquerque, and A. Campa, “Serum amyloid A is a growth factor for 3T3-L1 adipocytes, inhibits differentiation and promotes insulin resistance,” International Journal of Obesity, vol. 36, no. 8, pp. 1032–1039, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Ebeling, A.-M. Teppo, H. A. Koistinen et al., “Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes,” Diabetologia, vol. 42, no. 12, pp. 1433–1438, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Basu, A. Larsson, J. Vessby, B. Vessby, and C. Berne, “Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation,” Diabetes Care, vol. 28, no. 6, pp. 1371–1375, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Kinlay, G. G. Schwartz, A. G. Olsson et al., “High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study,” Circulation, vol. 108, no. 13, pp. 1560–1566, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Yoshida, A. M. Tabony, S. Galvez et al., “Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia,” International Journal of Biochemistry and Cell Biology, vol. 45, no. 10, pp. 2322–2332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. J. Lepedda, G. Nieddu, E. Zinellu et al., “Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid a as a potential marker,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 385214, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. E. S. Kilpatrick, A. S. Rigby, and S. L. Atkin, “Variability in the relationship between mean plasma glucose and HbA1c: implications for the assessment of glycemic control,” Clinical Chemistry, vol. 53, no. 5, pp. 897–901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. P. Davidsson, J. Hulthe, B. Fagerberg, and G. Camejo, “Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 2, pp. 156–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Y. Han, T. Chiba, J. S. Campbell et al., “Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 8, pp. 1806–1813, 2006. View at Publisher · View at Google Scholar · View at Scopus